<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Oncol</journal-id><journal-id journal-id-type="publisher-id">CO</journal-id><journal-title>Current Oncology</journal-title><issn pub-type="ppub">1198-0052</issn><publisher><publisher-name>Multimed Inc.</publisher-name> <publisher-loc>66 Martin St. Milton, ON, Canada L9T 2R2</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17593981</article-id><article-id pub-id-type="pmc">1899358</article-id><article-id pub-id-type="publisher-id">co14_3p089</article-id><article-categories><subj-group subj-group-type="heading"><subject>Canadian Centre Activities</subject></subj-group></article-categories><title-group><article-title>The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Richardson</surname><given-names>H.</given-names></name><degrees>PhD</degrees><xref rid="af1-co14_3p089" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name><surname>Johnston</surname><given-names>D.</given-names></name><degrees>PA</degrees><xref rid="af1-co14_3p089" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name><surname>Pater</surname><given-names>J.</given-names></name><degrees>MD MSc</degrees><xref rid="af1-co14_3p089" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name><surname>Goss</surname><given-names>P.</given-names></name><degrees>MD PhD</degrees><xref rid="af2-co14_3p089" ref-type="aff">†</xref><xref ref-type="corresp" rid="c1-co14_3p089"></xref></contrib><on-behalf-of>on behalf of the MAP.3 consortium</on-behalf-of></contrib-group><aff id="af1-co14_3p089"><label>*</label> National Cancer Institute of Canada Clinical Trials Group, Queen’s University, Kingston, Ontario</aff><aff id="af2-co14_3p089"><label>†</label> Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, U.S.A</aff><author-notes><corresp id="c1-co14_3p089">Correspondence to: Paul Goss, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Lawrence House, LRH-302, Boston, Massachusetts 02114 U.S.A. E-mail:
<email>pgoss@partners.org</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2007</year></pub-date><volume>14</volume><issue>3</issue><fpage>89</fpage><lpage>96</lpage><copyright-statement>2007 Multimed Inc.</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><p><offsets xml_i="3017" xml_f="3037" txt_i="11" txt_f="31">Several large phase </offsets><sc><offsets xml_i="3041" xml_f="3044" txt_i="31" txt_f="34">iii</offsets></sc><offsets xml_i="3049" xml_f="3369" txt_i="34" txt_f="354"> trials have demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these selective estrogen receptor modulators can also be associated with several rare, but serious, adverse events. Recently, the third-generation aromatase inhibitors (</offsets><sc><offsets xml_i="3373" xml_f="3375" txt_i="354" txt_f="356">ai</offsets></sc><offsets xml_i="3380" xml_f="3591" txt_i="356" txt_f="567">s) have demonstrated excellent efficacy in adjuvant breast cancer trials, and they show particular promise in the breast cancer prevention setting. The National Cancer Institute of Canada Clinical Trials Group (</offsets><sc><offsets xml_i="3595" xml_f="3603" txt_i="567" txt_f="575">ncic ctg</offsets></sc><offsets xml_i="3608" xml_f="3643" txt_i="575" txt_f="610">) has developed a randomized phase </offsets><sc><offsets xml_i="3647" xml_f="3650" txt_i="610" txt_f="613">iii</offsets></sc><offsets xml_i="3655" xml_f="3694" txt_i="613" txt_f="652"> study to determine the efficacy of an </offsets><sc><offsets xml_i="3698" xml_f="3700" txt_i="652" txt_f="654">ai</offsets></sc><offsets xml_i="3705" xml_f="3848" txt_i="654" txt_f="797"> (exemestane) to reduce the incidence of invasive breast cancer in postmenopausal women at an increased risk for developing breast cancer. The </offsets><sc><offsets xml_i="3852" xml_f="3864" txt_i="797" txt_f="809">ncic ctg map</offsets></sc><offsets xml_i="3869" xml_f="4016" txt_i="809" txt_f="956">.3 (ExCel) trial is a double-blind placebo-controlled multicentre, multinational trial. Based on the known preclinical and clinical profile of the </offsets><sc><offsets xml_i="4020" xml_f="4022" txt_i="956" txt_f="958">ai</offsets></sc><offsets xml_i="4027" xml_f="4177" txt_i="958" txt_f="1108">s, a greater reduction in breast cancer incidence with fewer side effects is hypothesized with this class of agents than with tamoxifen or raloxifene.</offsets></p></abstract><kwd-group><kwd>Aromatase inhibitors</kwd><kwd>breast cancer risk reduction</kwd><kwd>chemoprevention</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="4369" xml_f="4384" txt_i="1116" txt_f="1131">1. INTRODUCTION</offsets></title><p><offsets xml_i="4395" xml_f="4849" txt_i="1132" txt_f="1586">Breast cancer is one of the most frequently diagnosed malignancies in women worldwide. In North America, it represents about 30% of all cancers and about 20% of all cancer-related deaths. In the United States and Canada respectively, more than 200,000 and 20,000 new breast cancer cases are diagnosed annually, and beginning in the 1980s and continuing until very recently, the incidence of breast cancer was rising at a rate of approximately 2% per year</offsets><xref ref-type="bibr" rid="b1-co14_3p089"><offsets xml_i="4891" xml_f="4892" txt_i="1586" txt_f="1587">1</offsets></xref><offsets xml_i="4899" xml_f="4900" txt_i="1587" txt_f="1588">,</offsets><xref ref-type="bibr" rid="b2-co14_3p089"><offsets xml_i="4942" xml_f="4943" txt_i="1588" txt_f="1589">2</offsets></xref><offsets xml_i="4950" xml_f="4951" txt_i="1589" txt_f="1590">.</offsets></p><p><offsets xml_i="4958" xml_f="5261" txt_i="1591" txt_f="1894">The epidemiology of breast cancer is strongly influenced by genetic and environmental factors. Compared with other women, women with breast cancer are about twice as likely to have a first-degree relative with breast cancer, suggesting that the genetic factors are important determinants of disease risk</offsets><xref ref-type="bibr" rid="b3-co14_3p089"><offsets xml_i="5303" xml_f="5304" txt_i="1894" txt_f="1895">3</offsets></xref><offsets xml_i="5311" xml_f="5312" txt_i="1895" txt_f="1896">–</offsets><xref ref-type="bibr" rid="b5-co14_3p089"><offsets xml_i="5354" xml_f="5355" txt_i="1896" txt_f="1897">5</offsets></xref><offsets xml_i="5362" xml_f="5592" txt_i="1897" txt_f="2127">. However, large international differences in the rates of breast cancer and changes in the rates of disease in migrants from low-risk to high-risk countries suggest that environmental factors also play an important causative role</offsets><xref ref-type="bibr" rid="b6-co14_3p089"><offsets xml_i="5634" xml_f="5635" txt_i="2127" txt_f="2128">6</offsets></xref><offsets xml_i="5642" xml_f="5643" txt_i="2128" txt_f="2129">–</offsets><xref ref-type="bibr" rid="b8-co14_3p089"><offsets xml_i="5685" xml_f="5686" txt_i="2129" txt_f="2130">8</offsets></xref><offsets xml_i="5693" xml_f="5694" txt_i="2130" txt_f="2131">.</offsets></p><p><offsets xml_i="5701" xml_f="5980" txt_i="2132" txt_f="2411">Decades of epidemiologic and laboratory research have also identified that hormonal exposures are important in the complex origins of breast cancer. Hormonal events such as early age at menarche, late age at parity, and late onset of menopause can all increase breast cancer risk</offsets><sup><offsets xml_i="5985" xml_f="5989" txt_i="2411" txt_f="2415">9.10</offsets></sup><offsets xml_i="5995" xml_f="6229" txt_i="2415" txt_f="2649">. To date, most research has focused on endogenous sex steroid exposure, and higher levels of estrogen and androgens have been shown to be associated with a modest increase in the risk of breast cancer in pre- and postmenopausal women</offsets><xref ref-type="bibr" rid="b11-co14_3p089"><offsets xml_i="6272" xml_f="6274" txt_i="2649" txt_f="2651">11</offsets></xref><offsets xml_i="6281" xml_f="6282" txt_i="2651" txt_f="2652">–</offsets><xref ref-type="bibr" rid="b13-co14_3p089"><offsets xml_i="6325" xml_f="6327" txt_i="2652" txt_f="2654">13</offsets></xref><offsets xml_i="6334" xml_f="6402" txt_i="2654" txt_f="2722">. Interest in studying the roles of other hormones such as prolactin</offsets><xref ref-type="bibr" rid="b14-co14_3p089"><offsets xml_i="6445" xml_f="6447" txt_i="2722" txt_f="2724">14</offsets></xref><offsets xml_i="6454" xml_f="6499" txt_i="2724" txt_f="2769"> and the insulin–insulin-like growth factor (</offsets><sc><offsets xml_i="6503" xml_f="6506" txt_i="2769" txt_f="2772">igf</offsets></sc><offsets xml_i="6511" xml_f="6517" txt_i="2772" txt_f="2778">) axis</offsets><xref ref-type="bibr" rid="b15-co14_3p089"><offsets xml_i="6560" xml_f="6562" txt_i="2778" txt_f="2780">15</offsets></xref><offsets xml_i="6569" xml_f="6659" txt_i="2780" txt_f="2870"> is increasing, based on recent preclinical studies demonstrating the important role that </offsets><sc><offsets xml_i="6663" xml_f="6666" txt_i="2870" txt_f="2873">igf</offsets></sc><offsets xml_i="6671" xml_f="6747" txt_i="2873" txt_f="2949">-1 plays in stimulating the growth of prostate and breast cancer cells alike</offsets><xref ref-type="bibr" rid="b16-co14_3p089"><offsets xml_i="6790" xml_f="6792" txt_i="2949" txt_f="2951">16</offsets></xref><offsets xml_i="6799" xml_f="6800" txt_i="2951" txt_f="2952">.</offsets></p><p><offsets xml_i="6807" xml_f="7044" txt_i="2953" txt_f="3190">Many of the established risk factors currently identified for breast cancer cannot be easily modified. However, improved diet and reduced body weight, alcohol intake, hormone use, and mammographic density are examples of factors that can</offsets><xref ref-type="bibr" rid="b17-co14_3p089"><offsets xml_i="7087" xml_f="7089" txt_i="3190" txt_f="3192">17</offsets></xref><offsets xml_i="7096" xml_f="7097" txt_i="3192" txt_f="3193">–</offsets><xref ref-type="bibr" rid="b21-co14_3p089"><offsets xml_i="7140" xml_f="7142" txt_i="3193" txt_f="3195">21</offsets></xref><offsets xml_i="7149" xml_f="7411" txt_i="3195" txt_f="3457">. At the 29th annual San Antonio Breast Cancer Symposium, Dr. Ravdin and colleagues from the National Cancer Institute and Harbor University of California, Los Angeles Medical Center, reported on an overall 7% decline in breast cancer incidence from 2002 to 2003</offsets><xref ref-type="bibr" rid="b2-co14_3p089"><offsets xml_i="7453" xml_f="7454" txt_i="3457" txt_f="3458">2</offsets></xref><offsets xml_i="7461" xml_f="7703" txt_i="3458" txt_f="3700">, based on data from the Surveillance Epidemiology and Endpoints Results database. He noted that the decline was greatest in women over 50 years of age. Similar data have also been observed in California over the same time period and for 2004</offsets><xref ref-type="bibr" rid="b22-co14_3p089"><offsets xml_i="7746" xml_f="7748" txt_i="3700" txt_f="3702">22</offsets></xref><offsets xml_i="7755" xml_f="7756" txt_i="3702" txt_f="3703">.</offsets></p><p><offsets xml_i="7763" xml_f="7864" txt_i="3704" txt_f="3805">Dr. Ravdin and his team speculate that the dramatic reduction in use of hormone replacement therapy (</offsets><sc><offsets xml_i="7868" xml_f="7871" txt_i="3805" txt_f="3808">hrt</offsets></sc><offsets xml_i="7876" xml_f="8196" txt_i="3808" txt_f="4128">) in 2002 may be the best explanation for the reduction in breast cancer occurrence. Following the disappointing findings in 2002 from the Women’s Health Initiative Study of combination estrogen and progestin, which demonstrated a statistically significant increase (24%) in the breast cancer risk in the treatment arm, </offsets><sc><offsets xml_i="8200" xml_f="8203" txt_i="4128" txt_f="4131">hrt</offsets></sc><offsets xml_i="8208" xml_f="8256" txt_i="4131" txt_f="4179"> prescribing patterns were significantly altered</offsets><xref ref-type="bibr" rid="b20-co14_3p089"><offsets xml_i="8299" xml_f="8301" txt_i="4179" txt_f="4181">20</offsets></xref><offsets xml_i="8308" xml_f="8474" txt_i="4181" txt_f="4347">. Clarke and colleagues showed that hormone therapy use dropped 68% between 2001 and 2003 in California, and shortly thereafter breast cancer rates dropped by 10%–11%</offsets><xref ref-type="bibr" rid="b22-co14_3p089"><offsets xml_i="8517" xml_f="8519" txt_i="4347" txt_f="4349">22</offsets></xref><offsets xml_i="8526" xml_f="8563" txt_i="4349" txt_f="4386">. That decline was sustained in 2004.</offsets></p><p><offsets xml_i="8570" xml_f="8933" txt_i="4387" txt_f="4750">Breast cancer may take decades to grow, but many of these cancers are believed to be fuelled by hormones such as estrogen. By cutting the fuel supply, tumour growth is slowed down substantially—and possibly stopped. In turn, these tumours may be harder to detect by mammography. If estrogen can act as a promoter of tumour growth, it is possible that a change in </offsets><sc><offsets xml_i="8937" xml_f="8940" txt_i="4750" txt_f="4753">hrt</offsets></sc><offsets xml_i="8945" xml_f="9065" txt_i="4753" txt_f="4873"> use could translate into a full 7% reduction in breast cancer occurrence 1 year later, based on the high prevalence of </offsets><sc><offsets xml_i="9069" xml_f="9072" txt_i="4873" txt_f="4876">hrt</offsets></sc><offsets xml_i="9077" xml_f="9117" txt_i="4876" txt_f="4916"> use in postmenopausal women before 2002</offsets><xref ref-type="bibr" rid="b2-co14_3p089"><offsets xml_i="9159" xml_f="9160" txt_i="4916" txt_f="4917">2</offsets></xref><offsets xml_i="9167" xml_f="9168" txt_i="4917" txt_f="4918">.</offsets></p></sec><sec><title><offsets xml_i="9190" xml_f="9222" txt_i="4920" txt_f="4952">2. BREAST CANCER CHEMOPREVENTION</offsets></title><p><offsets xml_i="9233" xml_f="9553" txt_i="4953" txt_f="5273">The foregoing data and other epidemiologic studies have prompted researchers to hypothesize about strategies that may reduce the frequency of breast cancer. One logical strategy is to investigate agents capable of interfering with the initiation or promotion of the disease—in other words, breast cancer chemoprevention.</offsets></p><p><offsets xml_i="9560" xml_f="9808" txt_i="5274" txt_f="5522">To date, chemoprevention research has focused on strategies directed at antagonizing the effects of estrogens, because these hormones are known to play a key role both in the development of the normal breast and in the pathogenesis of breast cancer</offsets><xref ref-type="bibr" rid="b23-co14_3p089"><offsets xml_i="9851" xml_f="9853" txt_i="5522" txt_f="5524">23</offsets></xref><offsets xml_i="9860" xml_f="9861" txt_i="5524" txt_f="5525">,</offsets><xref ref-type="bibr" rid="b24-co14_3p089"><offsets xml_i="9904" xml_f="9906" txt_i="5525" txt_f="5527">24</offsets></xref><offsets xml_i="9913" xml_f="10138" txt_i="5527" txt_f="5752">. In principle, at least two pharmacologic approaches may be used to antagonize the effects of estrogen in the breast. The first is to inhibit estrogen binding to its receptor by using selective estrogen receptor modulators (</offsets><sc><offsets xml_i="10142" xml_f="10146" txt_i="5752" txt_f="5756">serm</offsets></sc><offsets xml_i="10151" xml_f="10339" txt_i="5756" txt_f="5944">s—tamoxifen and raloxifene). An alternative strategy of antagonizing (reducing) the effects of estrogen is to inhibit estrogen synthesis with an aromatase (estrogen synthetase) inhibitor (</offsets><sc><offsets xml_i="10343" xml_f="10345" txt_i="5944" txt_f="5946">ai</offsets></sc><offsets xml_i="10350" xml_f="10352" txt_i="5946" txt_f="5948">).</offsets></p><sec><title><offsets xml_i="10368" xml_f="10402" txt_i="5949" txt_f="5983">2.1 Inhibition of Estrogen Binding</offsets></title><p><offsets xml_i="10413" xml_f="10567" txt_i="5984" txt_f="6138">Tamoxifen and raloxifene have both been shown to reduce the incidence of invasive breast cancer by up to 50% in pre- and postmenopausal women at high risk</offsets><xref ref-type="bibr" rid="b25-co14_3p089"><offsets xml_i="10610" xml_f="10612" txt_i="6138" txt_f="6140">25</offsets></xref><offsets xml_i="10619" xml_f="10620" txt_i="6140" txt_f="6141">–</offsets><xref ref-type="bibr" rid="b27-co14_3p089"><offsets xml_i="10663" xml_f="10665" txt_i="6141" txt_f="6143">27</offsets></xref><offsets xml_i="10672" xml_f="10796" txt_i="6143" txt_f="6267">. Both drugs only reduce the incidence of estrogen receptor–positive breast cancer, consistent with their mode of action as </offsets><sc><offsets xml_i="10800" xml_f="10804" txt_i="6267" txt_f="6271">serm</offsets></sc><offsets xml_i="10809" xml_f="10890" txt_i="6271" txt_f="6352">s. As a result, tamoxifen was approved by the U.S. Food and Drug Administration (</offsets><sc><offsets xml_i="10894" xml_f="10897" txt_i="6352" txt_f="6355">fda</offsets></sc><offsets xml_i="10902" xml_f="10966" txt_i="6355" txt_f="6419">) for short-term reduction in the incidence of ductal carcinoma </offsets><italic><offsets xml_i="10974" xml_f="10981" txt_i="6419" txt_f="6426">in situ</offsets></italic><offsets xml_i="10990" xml_f="10992" txt_i="6426" txt_f="6428"> (</offsets><sc><offsets xml_i="10996" xml_f="11000" txt_i="6428" txt_f="6432">dcis</offsets></sc><offsets xml_i="11005" xml_f="11106" txt_i="6432" txt_f="6533">) and invasive breast cancer in women at increased risk. Raloxifene is currently under review by the </offsets><sc><offsets xml_i="11110" xml_f="11113" txt_i="6533" txt_f="6536">fda</offsets></sc><offsets xml_i="11118" xml_f="11395" txt_i="6536" txt_f="6813"> for approval as a second chemopreventive agent for women at high risk of developing invasive breast cancer. In fact, tamoxifen and raloxifene both appear effective in reducing breast cancer risk in “all risk” individuals as well, but approval for tamoxifen was granted by the </offsets><sc><offsets xml_i="11399" xml_f="11402" txt_i="6813" txt_f="6816">fda</offsets></sc><offsets xml_i="11407" xml_f="11653" txt_i="6816" txt_f="7062"> only for use in high-risk women because of its complicated therapeutic index. In particular, tamoxifen can cause rare, but serious, adverse events, including endometrial cancer and thromboembolic disease, especially in older postmenopausal women</offsets><xref ref-type="bibr" rid="b28-co14_3p089"><offsets xml_i="11696" xml_f="11698" txt_i="7062" txt_f="7064">28</offsets></xref><offsets xml_i="11705" xml_f="11706" txt_i="7064" txt_f="7065">.</offsets></p></sec><sec><title><offsets xml_i="11728" xml_f="11764" txt_i="7067" txt_f="7103">2.2 Inhibition of Estrogen Synthesis</offsets></title><p><offsets xml_i="11775" xml_f="11789" txt_i="7104" txt_f="7118">The effect of </offsets><sc><offsets xml_i="11793" xml_f="11795" txt_i="7118" txt_f="7120">ai</offsets></sc><offsets xml_i="11800" xml_f="11940" txt_i="7120" txt_f="7260">s on risk of breast cancer in postmenopausal women is currently under study. The National Cancer Institute of Canada Clinical Trials Group (</offsets><sc><offsets xml_i="11944" xml_f="11952" txt_i="7260" txt_f="7268">ncic ctg</offsets></sc><offsets xml_i="11957" xml_f="11959" txt_i="7268" txt_f="7270">) </offsets><sc><offsets xml_i="11963" xml_f="11966" txt_i="7270" txt_f="7273">map</offsets></sc><offsets xml_i="11971" xml_f="12185" txt_i="7273" txt_f="7487">.3 trial is one such study designed to examine the efficacy of exemestane versus placebo in postmenopausal women at increased risk of developing breast cancer. The International Breast Cancer Intervention Study 2 (</offsets><sc><offsets xml_i="12189" xml_f="12193" txt_i="7487" txt_f="7491">ibis</offsets></sc><offsets xml_i="12198" xml_f="12253" txt_i="7491" txt_f="7546"> 2), initiated in 2004, is the only other large, phase </offsets><sc><offsets xml_i="12257" xml_f="12260" txt_i="7546" txt_f="7549">iii</offsets></sc><offsets xml_i="12265" xml_f="12456" txt_i="7549" txt_f="7740"> trial designed to evaluate the efficacy of anastrozole as compared with placebo in preventing invasive breast cancer. It is underway in a similarly high-risk population in the United Kingdom</offsets><xref ref-type="bibr" rid="b29-co14_3p089"><offsets xml_i="12499" xml_f="12501" txt_i="7740" txt_f="7742">29</offsets></xref><offsets xml_i="12508" xml_f="12509" txt_i="7742" txt_f="7743">.</offsets></p></sec></sec><sec><title><offsets xml_i="12537" xml_f="12596" txt_i="7746" txt_f="7805">3. AROMATASE INHIBITORS AS POTENTIAL CHEMOPREVENTIVE AGENTS</offsets></title><p><offsets xml_i="12607" xml_f="12816" txt_i="7806" txt_f="8015">Targeting and reducing estrogen synthesis is a way of preventing estradiol from stimulating the estrogen receptor and of reducing the formation of cancer-causing catechol metabolites of estrogen. To that end, </offsets><sc><offsets xml_i="12820" xml_f="12822" txt_i="8015" txt_f="8017">ai</offsets></sc><offsets xml_i="12827" xml_f="12844" txt_i="8017" txt_f="8034">s were developed.</offsets></p><p><offsets xml_i="12851" xml_f="13003" txt_i="8035" txt_f="8187">Aromatase is the enzyme complex responsible for the final step in estrogen biosynthesis: the conversion of androgens to estrogens. The third-generation </offsets><sc><offsets xml_i="13007" xml_f="13009" txt_i="8187" txt_f="8189">ai</offsets></sc><offsets xml_i="13014" xml_f="13230" txt_i="8189" txt_f="8405">s letrozole, anastrozole, and exemestane are all approved for use in postmenopausal women with estrogen receptor–positive metastatic breast cancer that has progressed after tamoxifen or failed to respond to tamoxifen</offsets><xref ref-type="bibr" rid="b30-co14_3p089"><offsets xml_i="13273" xml_f="13275" txt_i="8405" txt_f="8407">30</offsets></xref><offsets xml_i="13282" xml_f="13283" txt_i="8407" txt_f="8408">–</offsets><xref ref-type="bibr" rid="b33-co14_3p089"><offsets xml_i="13326" xml_f="13328" txt_i="8408" txt_f="8410">33</offsets></xref><offsets xml_i="13335" xml_f="13444" txt_i="8410" txt_f="8519">, or as initial therapy in treatment-naïve women with receptor-positive metastatic disease. In addition, the </offsets><sc><offsets xml_i="13448" xml_f="13451" txt_i="8519" txt_f="8522">fda</offsets></sc><offsets xml_i="13456" xml_f="13680" txt_i="8522" txt_f="8746"> and Health Canada have approved anastrozole, exemestane, and letrozole for use as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer following varying periods of treatment with tamoxifen.</offsets></p><p><offsets xml_i="13687" xml_f="13740" txt_i="8747" txt_f="8800">At least eight adjuvant trials are currently testing </offsets><sc><offsets xml_i="13744" xml_f="13746" txt_i="8800" txt_f="8802">ai</offsets></sc><offsets xml_i="13751" xml_f="13853" txt_i="8802" txt_f="8904">s in early-stage postmenopausal receptor-positive breast cancer. Published data from four large phase </offsets><sc><offsets xml_i="13857" xml_f="13860" txt_i="8904" txt_f="8907">iii</offsets></sc><offsets xml_i="13865" xml_f="13933" txt_i="8907" txt_f="8975"> double-blind randomized adjuvant trials comparing third-generation </offsets><sc><offsets xml_i="13937" xml_f="13939" txt_i="8975" txt_f="8977">ai</offsets></sc><offsets xml_i="13944" xml_f="14032" txt_i="8977" txt_f="9065">s with tamoxifen or placebo after 5 or fewer years of tamoxifen are currently available.</offsets></p><p><offsets xml_i="14039" xml_f="14091" txt_i="9066" txt_f="9118">In the Arimidex, Tamoxifen Alone or in Combination (</offsets><sc><offsets xml_i="14095" xml_f="14099" txt_i="9118" txt_f="9122">atac</offsets></sc><offsets xml_i="14104" xml_f="14396" txt_i="9122" txt_f="9414">) trial, 9366 patients were randomly assigned to receive anastrozole and placebo, tamoxifen and placebo, or anastrozole and tamoxifen combined. Disease-free survival was significantly lengthened when the anastrozole group was compared with the tamoxifen group (absolute risk reduction: 2.7%; </offsets><italic><offsets xml_i="14404" xml_f="14405" txt_i="9414" txt_f="9415">p</offsets></italic><offsets xml_i="14414" xml_f="14623" txt_i="9415" txt_f="9624"> = 0.013) after a median follow-up of 47 months. Importantly, the incidence of new contralateral primary breast cancer was significantly lower in the anastrozole group than in the tamoxifen group [odds ratio (</offsets><sc><offsets xml_i="14627" xml_f="14629" txt_i="9624" txt_f="9626">or</offsets></sc><offsets xml_i="14634" xml_f="14643" txt_i="9626" txt_f="9635">): 0.42; </offsets><italic><offsets xml_i="14651" xml_f="14652" txt_i="9635" txt_f="9636">p</offsets></italic><offsets xml_i="14661" xml_f="14670" txt_i="9636" txt_f="9645"> = 0.007]</offsets><xref ref-type="bibr" rid="b34-co14_3p089"><offsets xml_i="14713" xml_f="14715" txt_i="9645" txt_f="9647">34</offsets></xref><offsets xml_i="14722" xml_f="14723" txt_i="9647" txt_f="9648">.</offsets></p><p><offsets xml_i="14730" xml_f="14763" txt_i="9649" txt_f="9682">The Intergroup Exemestane Study (</offsets><sc><offsets xml_i="14767" xml_f="14770" txt_i="9682" txt_f="9685">ies</offsets></sc><offsets xml_i="14775" xml_f="15109" txt_i="9685" txt_f="10019">) randomly assigned 4742 women who had received 2–3 years of tamoxifen to continue tamoxifen for a total of 5 years or to switch to exemestane to complete a 5-year course of hormonal therapy. After a median follow-up of 56 months, a significant improvement in disease-free survival was observed in the exemestane group [hazard ratio (</offsets><sc><offsets xml_i="15113" xml_f="15115" txt_i="10019" txt_f="10021">hr</offsets></sc><offsets xml_i="15120" xml_f="15154" txt_i="10021" txt_f="10055">): 0.76; 95% confidence interval (</offsets><sc><offsets xml_i="15158" xml_f="15160" txt_i="10055" txt_f="10057">ci</offsets></sc><offsets xml_i="15165" xml_f="15260" txt_i="10057" txt_f="10152">): 0.66 to 0.88], together with a significant reduction in contralateral breast cancer events (</offsets><sc><offsets xml_i="15264" xml_f="15266" txt_i="10152" txt_f="10154">hr</offsets></sc><offsets xml_i="15271" xml_f="15283" txt_i="10154" txt_f="10166">: 0.56; 95% </offsets><sc><offsets xml_i="15287" xml_f="15289" txt_i="10166" txt_f="10168">ci</offsets></sc><offsets xml_i="15294" xml_f="15310" txt_i="10168" txt_f="10184">: 0.32 to 0.97) </offsets><xref ref-type="bibr" rid="b35-co14_3p089"><offsets xml_i="15353" xml_f="15355" txt_i="10184" txt_f="10186">35</offsets></xref><offsets xml_i="15362" xml_f="15408" txt_i="10186" txt_f="10232"> and a modest improvement in overall survival </offsets><xref ref-type="bibr" rid="b36-co14_3p089"><offsets xml_i="15451" xml_f="15453" txt_i="10232" txt_f="10234">36</offsets></xref><offsets xml_i="15460" xml_f="15461" txt_i="10234" txt_f="10235">.</offsets></p><p><offsets xml_i="15468" xml_f="15472" txt_i="10236" txt_f="10240">The </offsets><sc><offsets xml_i="15476" xml_f="15487" txt_i="10240" txt_f="10251">ncic ctg ma</offsets></sc><offsets xml_i="15492" xml_f="15874" txt_i="10251" txt_f="10633">.17 trial involved 5187 postmenopausal women who had taken tamoxifen for 5 years and who were disease free at time of study entry. They were randomly assigned to receive 5 years of letrozole or 5 years of placebo. The study was halted by the Data Safety Monitoring Committee after a median of 2.4 years because of a significant reduction in breast cancer events in the treatment arm</offsets><xref ref-type="bibr" rid="b37-co14_3p089"><offsets xml_i="15917" xml_f="15919" txt_i="10633" txt_f="10635">37</offsets></xref><offsets xml_i="15926" xml_f="16245" txt_i="10635" txt_f="10954">. More recently, the study demonstrated an overall benefit in distant disease-free survival and a survival advantage in the subset of women on the trial who had node-positive disease. The incidence of contralateral cancers was also lower in the letrozole group, although the difference was not statistically significant</offsets><xref ref-type="bibr" rid="b38-co14_3p089"><offsets xml_i="16288" xml_f="16290" txt_i="10954" txt_f="10956">38</offsets></xref><offsets xml_i="16297" xml_f="16298" txt_i="10956" txt_f="10957">.</offsets></p><p><offsets xml_i="16305" xml_f="16845" txt_i="10958" txt_f="11498">The Breast Cancer International Study Group involved approximately 8000 women and had four treatment arms: tamoxifen alone for 5 years, letrozole alone for 5 years, tamoxifen for 3 years followed by letrozole for 2 years, and letrozole for 3 years followed by tamoxifen for 2 years. A recent analysis comparing letrozole to tamoxifen treatment showed that the reduction in risk of recurrence or death was 19% lower in the letrozole-alone group after a median of 28 months of follow-up. Comparisons of the switched arms are not yet available</offsets><xref ref-type="bibr" rid="b39-co14_3p089"><offsets xml_i="16888" xml_f="16890" txt_i="11498" txt_f="11500">39</offsets></xref><offsets xml_i="16897" xml_f="16898" txt_i="11500" txt_f="11501">.</offsets></p><p><offsets xml_i="16905" xml_f="17100" txt_i="11502" txt_f="11697">Based on results from these large trials and other smaller randomized trials, the Technology Assessment of Aromatase Inhibitors Status Report 2004 from the American Society of Clinical Oncology (</offsets><sc><offsets xml_i="17104" xml_f="17108" txt_i="11697" txt_f="11701">asco</offsets></sc><offsets xml_i="17113" xml_f="17267" txt_i="11701" txt_f="11855">) recommends that, to lower the risk of recurrence, adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer should include </offsets><sc><offsets xml_i="17271" xml_f="17273" txt_i="11855" txt_f="11857">ai</offsets></sc><offsets xml_i="17278" xml_f="17316" txt_i="11857" txt_f="11895">s. The optimal timing and duration of </offsets><sc><offsets xml_i="17320" xml_f="17322" txt_i="11895" txt_f="11897">ai</offsets></sc><offsets xml_i="17327" xml_f="17361" txt_i="11897" txt_f="11931"> therapy has yet to be established</offsets><xref ref-type="bibr" rid="b40-co14_3p089"><offsets xml_i="17404" xml_f="17406" txt_i="11931" txt_f="11933">40</offsets></xref><offsets xml_i="17413" xml_f="17414" txt_i="11933" txt_f="11934">.</offsets></p><p><offsets xml_i="17421" xml_f="17463" txt_i="11935" txt_f="11977">The thus-far convincing evidence that the </offsets><sc><offsets xml_i="17467" xml_f="17469" txt_i="11977" txt_f="11979">ai</offsets></sc><offsets xml_i="17474" xml_f="17630" txt_i="11979" txt_f="12135">s are superior to tamoxifen in the treatment of breast cancer has suggested that they will also perhaps prove to be superior in the chemopreventive setting.</offsets></p><p><offsets xml_i="17637" xml_f="17937" txt_i="12136" txt_f="12436">Exemestane is a third-generation irreversible steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. In postmenopausal women, exemestane is capable of inhibiting aromatase action by more than 95%. The reduction in contralateral breast cancer incidence in the </offsets><sc><offsets xml_i="17941" xml_f="17945" txt_i="12436" txt_f="12440">atac</offsets></sc><offsets xml_i="17950" xml_f="17955" txt_i="12440" txt_f="12445"> and </offsets><sc><offsets xml_i="17959" xml_f="17962" txt_i="12445" txt_f="12448">ies</offsets></sc><offsets xml_i="17967" xml_f="18014" txt_i="12448" txt_f="12495"> trials is especially promising in this regard.</offsets></p><p><offsets xml_i="18021" xml_f="18122" txt_i="12496" txt_f="12597">In addition to the clinical studies, a significant body of data on the chemopreventive properties of </offsets><sc><offsets xml_i="18126" xml_f="18128" txt_i="12597" txt_f="12599">ai</offsets></sc><offsets xml_i="18133" xml_f="18165" txt_i="12599" txt_f="12631">s comes from preclinical studies</offsets><xref ref-type="bibr" rid="b41-co14_3p089"><offsets xml_i="18208" xml_f="18210" txt_i="12631" txt_f="12633">41</offsets></xref><offsets xml_i="18217" xml_f="18218" txt_i="12633" txt_f="12634">–</offsets><xref ref-type="bibr" rid="b44-co14_3p089"><offsets xml_i="18261" xml_f="18263" txt_i="12634" txt_f="12636">44</offsets></xref><offsets xml_i="18270" xml_f="18271" txt_i="12636" txt_f="12637">.</offsets></p></sec><sec><title><offsets xml_i="18293" xml_f="18310" txt_i="12639" txt_f="12656">4. NCIC CTG MAP.3</offsets></title><p><offsets xml_i="18321" xml_f="18325" txt_i="12657" txt_f="12661">The </offsets><sc><offsets xml_i="18329" xml_f="18332" txt_i="12661" txt_f="12664">map</offsets></sc><offsets xml_i="18337" xml_f="18355" txt_i="12664" txt_f="12682">.3 (ExCel) trial (</offsets><ext-link ext-link-type="uri" xlink:href="www.excelstudy.com"><offsets xml_i="18417" xml_f="18435" txt_i="12682" txt_f="12700">www.excelstudy.com</offsets></ext-link><offsets xml_i="18446" xml_f="18547" txt_i="12700" txt_f="12801">) is a randomized double-blind placebo-controlled, multicentre, multinational trial sponsored by the </offsets><sc><offsets xml_i="18551" xml_f="18559" txt_i="12801" txt_f="12809">ncic ctg</offsets></sc><offsets xml_i="18564" xml_f="18654" txt_i="12809" txt_f="12899"> and supported by Pfizer Inc. Based on the known pre-clinical and clinical profile of the </offsets><sc><offsets xml_i="18658" xml_f="18660" txt_i="12899" txt_f="12901">ai</offsets></sc><offsets xml_i="18665" xml_f="18791" txt_i="12901" txt_f="13027">s, a greater reduction in breast cancer incidence is hypothesized with this class of agents than with tamoxifen or raloxifene.</offsets></p><sec sec-type="methods"><title><offsets xml_i="18826" xml_f="18842" txt_i="13028" txt_f="13044">4.1 Study Design</offsets></title><p><offsets xml_i="18853" xml_f="18953" txt_i="13045" txt_f="13145">The initial intent was to compare exemestane (25 mg) in combination with a cyclooxygenase enzyme 2 (</offsets><sc><offsets xml_i="18957" xml_f="18960" txt_i="13145" txt_f="13148">cox</offsets></sc><offsets xml_i="18965" xml_f="19087" txt_i="13148" txt_f="13270">-2) inhibitor, celecoxib (400 mg); exemestane (25 mg) in combination with a placebo; and a placebo (2 tablets) in a phase </offsets><sc><offsets xml_i="19091" xml_f="19094" txt_i="13270" txt_f="13273">iii</offsets></sc><offsets xml_i="19099" xml_f="19290" txt_i="13273" txt_f="13464"> randomized trial, in 5100 post-menopausal women at increased risk of developing breast cancer. The rationale for incorporating celecoxib into the trial design was based on observations that </offsets><sc><offsets xml_i="19294" xml_f="19297" txt_i="13464" txt_f="13467">cox</offsets></sc><offsets xml_i="19302" xml_f="19373" txt_i="13467" txt_f="13538">-2 is overexpressed in breast cancer and in pre-invasive breast lesions</offsets><xref ref-type="bibr" rid="b45-co14_3p089"><offsets xml_i="19416" xml_f="19418" txt_i="13538" txt_f="13540">45</offsets></xref><offsets xml_i="19425" xml_f="19426" txt_i="13540" txt_f="13541">–</offsets><xref ref-type="bibr" rid="b47-co14_3p089"><offsets xml_i="19469" xml_f="19471" txt_i="13541" txt_f="13543">47</offsets></xref><offsets xml_i="19478" xml_f="19591" txt_i="13543" txt_f="13656">, and that a meta-analysis of 14 cohort and case-control studies had found a combined relative risk of 0.82 (95% </offsets><sc><offsets xml_i="19595" xml_f="19597" txt_i="13656" txt_f="13658">ci</offsets></sc><offsets xml_i="19602" xml_f="19684" txt_i="13658" txt_f="13740">: 0.75 to 0.89) for developing breast cancer in women who had a history of taking </offsets><sc><offsets xml_i="19688" xml_f="19691" txt_i="13740" txt_f="13743">cox</offsets></sc><offsets xml_i="19696" xml_f="19709" txt_i="13743" txt_f="13756">-2 inhibitors</offsets><xref ref-type="bibr" rid="b48-co14_3p089"><offsets xml_i="19752" xml_f="19754" txt_i="13756" txt_f="13758">48</offsets></xref><offsets xml_i="19761" xml_f="20008" txt_i="13758" txt_f="14005">. Further-more, in preclinical studies, a synergistic effect appeared to exist between celecoxib and exemestane, resulting in a greater ability to prevent new tumours and to reduce the existing tumour burden in animals when the drugs were combined</offsets><xref ref-type="bibr" rid="b49-co14_3p089"><offsets xml_i="20051" xml_f="20053" txt_i="14005" txt_f="14007">49</offsets></xref><offsets xml_i="20060" xml_f="20083" txt_i="14007" txt_f="14030">. At the time that the </offsets><sc><offsets xml_i="20087" xml_f="20090" txt_i="14030" txt_f="14033">map</offsets></sc><offsets xml_i="20095" xml_f="20177" txt_i="14033" txt_f="14115">.3 protocol was developed, celecoxib was considered to be well tolerated and safe.</offsets></p><p><offsets xml_i="20184" xml_f="20398" txt_i="14116" txt_f="14330">Each of the three arms was to be tested separately and consecutively. Celecoxib–placebo was to be prescribed for a total of 3 years, and exemestane–placebo was to be prescribed for a total of 5 years. The original </offsets><sc><offsets xml_i="20402" xml_f="20405" txt_i="14330" txt_f="14333">map</offsets></sc><offsets xml_i="20410" xml_f="20525" txt_i="14333" txt_f="14448">.3 protocol was activated in 2004, and the first 35 participants were enrolled between September and November 2004.</offsets></p><p><offsets xml_i="20532" xml_f="20629" txt_i="14449" txt_f="14546">Unfortunately, in September 2004, early results from a colorectal adenoma chemoprevention trial (</offsets><sc><offsets xml_i="20633" xml_f="20639" txt_i="14546" txt_f="14552">approv</offsets></sc><offsets xml_i="20644" xml_f="20646" txt_i="14552" txt_f="14554">e)</offsets><xref ref-type="bibr" rid="b50-co14_3p089"><offsets xml_i="20689" xml_f="20691" txt_i="14554" txt_f="14556">50</offsets></xref><offsets xml_i="20698" xml_f="21042" txt_i="14556" txt_f="14900"> showed an elevated cardiovascular risk in subjects with a history of colorectal adenomas who were taking rofecoxib (Vioxx: Merck, Whitehouse Station, NJ, U.S.A.), which, until that point, had been considered a very promising chemopreventive agent for colorectal adenomas. In late December, data from the Adenoma Prevention with Celecoxib trial</offsets><xref ref-type="bibr" rid="b51-co14_3p089"><offsets xml_i="21085" xml_f="21087" txt_i="14900" txt_f="14902">51</offsets></xref><offsets xml_i="21094" xml_f="21185" txt_i="14902" txt_f="14993"> showed a similar association between celecoxib and cardiovascular risk. Consequently, the </offsets><sc><offsets xml_i="21189" xml_f="21192" txt_i="14993" txt_f="14996">map</offsets></sc><offsets xml_i="21197" xml_f="21269" txt_i="14996" txt_f="15068">.3 steering committee decided to halt the trial and revise the protocol.</offsets></p><p><offsets xml_i="21276" xml_f="21288" txt_i="15069" txt_f="15081">The revised </offsets><sc><offsets xml_i="21292" xml_f="21295" txt_i="15081" txt_f="15084">map</offsets></sc><offsets xml_i="21300" xml_f="21737" txt_i="15084" txt_f="15521">.3 study now compares exemestane to placebo in a 1:1 ratio in 4560 postmenopausal women who are 35 years of age or older and at increased risk for the development of breast cancer. For the purposes of this protocol, “increased risk” is defined as being over the age of 60, or having a Gail score greater than 1.65, or having a prior atypical breast biopsy (atypical ductal hyperplasia, atypical lobular hyperplasia, or lobular carcinoma </offsets><italic><offsets xml_i="21745" xml_f="21752" txt_i="15521" txt_f="15528">in situ</offsets></italic><offsets xml_i="21761" xml_f="21795" txt_i="15528" txt_f="15562">), or having a prior diagnosis of </offsets><sc><offsets xml_i="21799" xml_f="21803" txt_i="15562" txt_f="15566">dcis</offsets></sc><offsets xml_i="21808" xml_f="22033" txt_i="15566" txt_f="15785"> that was treated with a mastectomy. Women are stratified on their Gail score (≤ 2 vs. &gt;2) and current low-dose (&lt;100 mg daily) aspirin use (yes vs. no) before being randomly allocated to the treatment or placebo group.</offsets></p></sec><sec><title><offsets xml_i="22055" xml_f="22080" txt_i="15787" txt_f="15812">4.2 Rationale for Placebo</offsets></title><p><offsets xml_i="22091" xml_f="22315" txt_i="15813" txt_f="16037">Despite the fact that tamoxifen has been approved as a means to reduce breast cancer risk in women who would be eligible for this trial, it was decided that the use of a placebo control arm was justified for several reasons:</offsets></p><list list-type="bullet"><list-item><p><offsets xml_i="22358" xml_f="22594" txt_i="16038" txt_f="16274">Although tamoxifen is approved for the indication of reducing the short-term incidence of breast cancer, many women whose level of risk would qualify them for the prescription of tamoxifen refuse the drug because of its toxicity profile</offsets><xref ref-type="bibr" rid="b52-co14_3p089"><offsets xml_i="22637" xml_f="22639" txt_i="16274" txt_f="16276">52</offsets></xref><offsets xml_i="22646" xml_f="22647" txt_i="16276" txt_f="16277">–</offsets><xref ref-type="bibr" rid="b55-co14_3p089"><offsets xml_i="22690" xml_f="22692" txt_i="16277" txt_f="16279">55</offsets></xref><offsets xml_i="22699" xml_f="23027" txt_i="16279" txt_f="16607">. Raloxifene is another option that women may consider for breast cancer risk reduction, although it is not yet approved for that indication. However, although the risk profile for raloxifene may be better than that for tamoxifen, it is still associated with increased risk of thromboembolic events and decreased sexual function</offsets><xref ref-type="bibr" rid="b27-co14_3p089"><offsets xml_i="23070" xml_f="23072" txt_i="16607" txt_f="16609">27</offsets></xref><offsets xml_i="23079" xml_f="23395" txt_i="16609" txt_f="16925">. Therefore, there remains a population of women eligible for this trial who have chosen or will choose, even after appropriate counselling, to avoid taking tamoxifen or raloxifene. These women may well wish to enter a placebo-controlled trial where the agents under study may have more favourable toxicity profiles.</offsets></p></list-item><list-item><p><offsets xml_i="23425" xml_f="23429" txt_i="16926" txt_f="16930">The </offsets><sc><offsets xml_i="23433" xml_f="23437" txt_i="16930" txt_f="16934">asco</offsets></sc><offsets xml_i="23442" xml_f="23585" txt_i="16934" txt_f="17077"> Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene and Aromatase Inhibition</offsets><xref ref-type="bibr" rid="b56-co14_3p089"><offsets xml_i="23628" xml_f="23630" txt_i="17077" txt_f="17079">56</offsets></xref><offsets xml_i="23637" xml_f="23829" txt_i="17079" txt_f="17271"> concluded that “placebo controls are appropriate for breast cancer risk reduction trials since no intervention has been demonstrated to favorably impact net health or survival.” Although the </offsets><sc><offsets xml_i="23833" xml_f="23836" txt_i="17271" txt_f="17274">map</offsets></sc><offsets xml_i="23841" xml_f="24018" txt_i="17274" txt_f="17451">.3 trial is not expected to demonstrate an impact on survival, the results may well indicate a more favourable therapeutic ratio for exemestane than for tamoxifen or raloxifene.</offsets></p></list-item><list-item><p><offsets xml_i="24048" xml_f="24233" txt_i="17452" txt_f="17637">The placebo arm will allow for a true determination of efficacy in reducing invasive breast cancer, of adverse effects, and of impact on overall and menopausal-specific quality of life.</offsets></p></list-item></list></sec><sec sec-type="methods"><title><offsets xml_i="24293" xml_f="24313" txt_i="17639" txt_f="17659">4.3 Study Procedures</offsets></title><p><offsets xml_i="24324" xml_f="24346" txt_i="17660" txt_f="17682">Women enrolled in the </offsets><sc><offsets xml_i="24350" xml_f="24353" txt_i="17682" txt_f="17685">map</offsets></sc><offsets xml_i="24358" xml_f="25185" txt_i="17685" txt_f="18512">.3 research study will have a bone-mineral density test and a mammogram before being randomized. Women can be enrolled at centres in Canada, the United States, or Spain. Participants will be asked to return to their local study centre twice during the first year, at 6 and 12 months, and then annually for follow-up visits for the remaining 4 years of the study. At each visit, participants will be given a new supply of the study medications and will be asked to answer questions about their quality of life and about any illnesses or discomfort they may have experienced since their last visit. At each annual visit, participants will undergo a physical and health exam and a mammogram. At three different times during the study, serum samples will also be taken for hormone testing. If additional consent has been given for </offsets><sc><offsets xml_i="25189" xml_f="25192" txt_i="18512" txt_f="18515">dna</offsets></sc><offsets xml_i="25197" xml_f="25282" txt_i="18515" txt_f="18600"> testing, a blood sample taken at baseline will be stored for future genetic testing.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="25323" xml_f="25353" txt_i="18602" txt_f="18632">4.4 Study Goals and Population</offsets></title><p><offsets xml_i="25364" xml_f="25390" txt_i="18633" txt_f="18659">The main objective of the </offsets><sc><offsets xml_i="25394" xml_f="25397" txt_i="18659" txt_f="18662">map</offsets></sc><offsets xml_i="25402" xml_f="25837" txt_i="18662" txt_f="19097">.3 trial is to compare the incidence of breast cancer in the two treatment groups. Information will also be recorded and compared between treatment groups on clinical bone fractures, cardiovascular events, quality of life, tolerability and safety, and incidences of other malignancies. A companion study to evaluate the long-term effects of exemestane on bone density and bone biomarkers is planned for a subset of participating sites.</offsets></p><p><offsets xml_i="25844" xml_f="26640" txt_i="19098" txt_f="19894">Some of the biggest challenges of conducting a breast cancer prevention trial include recruiting women from the general population and defining the groups at high-risk for the development of breast cancer that are most eligible for chemoprevention. Well established cancer cooperative groups with affiliated clinical research centers in North America, Europe, and Australia are available to help with recruitment of cancer patients into therapeutic trials. However, that model is not so easy to replicate for cancer prevention trials. The clinicians that typically see well women are more likely to be primary care physicians or other internal specialists such as gynecologists. However, primary care physicians in particular do not appear to be comfortable prescribing chemoprevention medication</offsets><xref ref-type="bibr" rid="b57-co14_3p089"><offsets xml_i="26683" xml_f="26685" txt_i="19894" txt_f="19896">57</offsets></xref><offsets xml_i="26692" xml_f="26693" txt_i="19896" txt_f="19897">–</offsets><xref ref-type="bibr" rid="b59-co14_3p089"><offsets xml_i="26736" xml_f="26738" txt_i="19897" txt_f="19899">59</offsets></xref><offsets xml_i="26745" xml_f="26947" txt_i="19899" txt_f="20101">, and based on results from a recent national survey in the United States, the decision to prescribe tamoxifen was greatly affected by logistics and the ability of the physician to determine eligibility</offsets><xref ref-type="bibr" rid="b59-co14_3p089"><offsets xml_i="26990" xml_f="26992" txt_i="20101" txt_f="20103">59</offsets></xref><offsets xml_i="26999" xml_f="27000" txt_i="20103" txt_f="20104">.</offsets></p><p><offsets xml_i="27007" xml_f="27015" txt_i="20105" txt_f="20113">For the </offsets><sc><offsets xml_i="27019" xml_f="27022" txt_i="20113" txt_f="20116">map</offsets></sc><offsets xml_i="27027" xml_f="27056" txt_i="20116" txt_f="20145">.3 trial to be feasible, the </offsets><sc><offsets xml_i="27060" xml_f="27068" txt_i="20145" txt_f="20153">ncic ctg</offsets></sc><offsets xml_i="27073" xml_f="27297" txt_i="20153" txt_f="20377"> had to assemble a consortium of clinical researchers in Canada and the United States who were committed to cancer prevention research and who had participated in earlier prevention trials with the Women’s Heath Initiative (</offsets><sc><offsets xml_i="27301" xml_f="27304" txt_i="20377" txt_f="20380">whi</offsets></sc><offsets xml_i="27309" xml_f="27612" txt_i="20380" txt_f="20683">) or the National Surgical Adjuvant Breast and Bowel Project. Nonetheless, recruiting to chemoprevention trials is still very challenging, even for experienced research centres. To be successful, each site must consider numerous recruitment strategies. Some of the most successful strategies to date on </offsets><sc><offsets xml_i="27616" xml_f="27619" txt_i="20683" txt_f="20686">map</offsets></sc><offsets xml_i="27624" xml_f="27766" txt_i="20686" txt_f="20828">.3 include mass mailings, targeting of high-risk screening clinics, and targeting of “enriched” lists (that is, women who participated in the </offsets><sc><offsets xml_i="27770" xml_f="27773" txt_i="20828" txt_f="20831">whi</offsets></sc><offsets xml_i="27778" xml_f="27880" txt_i="20831" txt_f="20933"> observational study and expressed an interest in participating in future cancer prevention research).</offsets></p><p><offsets xml_i="27887" xml_f="28372" txt_i="20934" txt_f="21419">Cancer prevention trials tend to be dauntingly large, particularly if cancer is the primary endpoint. The large sample size is necessary because cancer is a very rare occurrence in the general population, and there is a need to complete the study in a reasonable period of time (that is, 5 years). Selecting a study sample that has a higher-than-average risk of developing cancer is one strategy to increase the event rate in a fixed period and thereby reduce the required sample size.</offsets></p><p><offsets xml_i="28379" xml_f="28617" txt_i="21420" txt_f="21658">Risk prediction models can be included in the design of chemoprevention studies to help identify high-risk populations for an assessment of the effects of interventions and construction of risk–benefit indices for preventive interventions</offsets><xref ref-type="bibr" rid="b60-co14_3p089"><offsets xml_i="28660" xml_f="28662" txt_i="21658" txt_f="21660">60</offsets></xref><offsets xml_i="28669" xml_f="28747" txt_i="21660" txt_f="21738">. The Gail model is one such existing model that has modest predictive ability</offsets><xref ref-type="bibr" rid="b61-co14_3p089"><offsets xml_i="28790" xml_f="28792" txt_i="21738" txt_f="21740">61</offsets></xref><offsets xml_i="28799" xml_f="29175" txt_i="21740" txt_f="22116">. Based on six well-established risk factors (age, age at menarche, age at first birth, first-degree family history of breast cancer, prior breast biopsy, and race), the Gail model calculates a woman’s 5-year risk (probability) of developing breast cancer and compares it with the average risk for a woman of the same age and race or ethnicity from the general U.S. population</offsets><xref ref-type="bibr" rid="b62-co14_3p089"><offsets xml_i="29218" xml_f="29220" txt_i="22116" txt_f="22118">62</offsets></xref><offsets xml_i="29227" xml_f="29228" txt_i="22118" txt_f="22119">.</offsets></p><p><offsets xml_i="29235" xml_f="29737" txt_i="22120" txt_f="22622">Age is one of the most important risk factors for breast cancer. An average 60-year-old woman has a Gail score of 1.8%; an average 35-year-old woman has a Gail score of 0.3%. By designing a prevention trial with a minimum Gail score requirement of 1.66% for women who are under 60 years of age and have no history of benign breast disease, the expected annual incidence rate (event rate) in the placebo group (0.60%) will be more than 6 times the annual incidence rate in the general population (0.10%)</offsets><xref ref-type="bibr" rid="b63-co14_3p089"><offsets xml_i="29780" xml_f="29782" txt_i="22622" txt_f="22624">63</offsets></xref><offsets xml_i="29789" xml_f="29980" txt_i="22624" txt_f="22815">. Admittedly, estimates of risk could be greatly improved with the addition of specific genetic profiles with validated candidate genes, of lifestyle risk factors, and of mammographic density</offsets><xref ref-type="bibr" rid="b64-co14_3p089"><offsets xml_i="30023" xml_f="30025" txt_i="22815" txt_f="22817">64</offsets></xref><offsets xml_i="30032" xml_f="30249" txt_i="22817" txt_f="23034">. However, the appeal of the Gail model is that it is reliable, cost-efficient, and easy to use in large-scale breast cancer prevention trials, in which thousands of women need to be screened to determine eligibility.</offsets></p></sec></sec><sec sec-type="conclusions"><title><offsets xml_i="30300" xml_f="30310" txt_i="23037" txt_f="23047">5. SUMMARY</offsets></title><p><offsets xml_i="30321" xml_f="30397" txt_i="23048" txt_f="23124">In the 15 years since the first breast cancer prevention trial was initiated</offsets><xref ref-type="bibr" rid="b25-co14_3p089"><offsets xml_i="30440" xml_f="30442" txt_i="23124" txt_f="23126">25</offsets></xref><offsets xml_i="30449" xml_f="30471" txt_i="23126" txt_f="23148">, several large phase </offsets><sc><offsets xml_i="30475" xml_f="30478" txt_i="23148" txt_f="23151">iii</offsets></sc><offsets xml_i="30483" xml_f="30653" txt_i="23151" txt_f="23321"> trials have consistently demonstrated that tamoxifen—and more recently, raloxifene—can effectively reduce the incidence of invasive breast cancer by 50%. However, these </offsets><sc><offsets xml_i="30657" xml_f="30661" txt_i="23321" txt_f="23325">serm</offsets></sc><offsets xml_i="30666" xml_f="30802" txt_i="23325" txt_f="23461">s can also be associated with several rare, but serious adverse events, which may explain their low uptake for chemopreventive purposes.</offsets></p><p><offsets xml_i="30809" xml_f="30876" txt_i="23462" txt_f="23529">Currently, a great deal of interest exists in the third-generation </offsets><sc><offsets xml_i="30880" xml_f="30882" txt_i="23529" txt_f="23531">ai</offsets></sc><offsets xml_i="30887" xml_f="31153" txt_i="23531" txt_f="23797">s. These agents have demonstrated excellent efficacy in adjuvant breast cancer trials and show particular promise in the breast cancer prevention setting, based on the significantly higher reduction rates for contralateral breast cancer in the groups of women on an </offsets><sc><offsets xml_i="31157" xml_f="31159" txt_i="23797" txt_f="23799">ai</offsets></sc><offsets xml_i="31164" xml_f="31191" txt_i="23799" txt_f="23826"> than in those on tamoxifen</offsets><xref ref-type="bibr" rid="b34-co14_3p089"><offsets xml_i="31234" xml_f="31236" txt_i="23826" txt_f="23828">34</offsets></xref><offsets xml_i="31243" xml_f="31244" txt_i="23828" txt_f="23829">,</offsets><xref ref-type="bibr" rid="b35-co14_3p089"><offsets xml_i="31287" xml_f="31289" txt_i="23829" txt_f="23831">35</offsets></xref><offsets xml_i="31296" xml_f="31297" txt_i="23831" txt_f="23832">.</offsets></p><p><offsets xml_i="31304" xml_f="31308" txt_i="23833" txt_f="23837">The </offsets><sc><offsets xml_i="31312" xml_f="31314" txt_i="23837" txt_f="23839">ai</offsets></sc><offsets xml_i="31319" xml_f="31555" txt_i="23839" txt_f="24075">s are generally well tolerated. Side effects are similar to those of decreased estrogen—hot flashes, increased blood pressure, and thinning of bones, for example. However, the toxicity profile of exemestane may have advantages over the </offsets><sc><offsets xml_i="31559" xml_f="31563" txt_i="24075" txt_f="24079">serm</offsets></sc><offsets xml_i="31568" xml_f="31584" txt_i="24079" txt_f="24095">s and the other </offsets><sc><offsets xml_i="31588" xml_f="31590" txt_i="24095" txt_f="24097">ai</offsets></sc><offsets xml_i="31595" xml_f="31798" txt_i="24097" txt_f="24300">s. To date, no evidence has been uncovered that, as compared with placebo or tamoxifen, exemestane is associated with any significant increase in cardiovascular disease or adverse effect on lipid profile</offsets><xref ref-type="bibr" rid="b65-co14_3p089"><offsets xml_i="31841" xml_f="31843" txt_i="24300" txt_f="24302">65</offsets></xref><offsets xml_i="31850" xml_f="31981" txt_i="24302" txt_f="24433">. In addition, because of the weak androgenic and anabolic properties of the principal metabolite of exemestane, 17-hydroexemestane</offsets><xref ref-type="bibr" rid="b66-co14_3p089"><offsets xml_i="32024" xml_f="32026" txt_i="24433" txt_f="24435">66</offsets></xref><offsets xml_i="32033" xml_f="32111" txt_i="24435" txt_f="24513">, exemestane may have fewer negative effects on bone metabolism than do other </offsets><sc><offsets xml_i="32115" xml_f="32117" txt_i="24513" txt_f="24515">ai</offsets></sc><offsets xml_i="32122" xml_f="32124" txt_i="24515" txt_f="24517">s.</offsets></p><p><offsets xml_i="32131" xml_f="32199" txt_i="24518" txt_f="24586">Although it is too early to speculate about the overall efficacy of </offsets><sc><offsets xml_i="32203" xml_f="32205" txt_i="24586" txt_f="24588">ai</offsets></sc><sc><offsets xml_i="32214" xml_f="32217" txt_i="24588" txt_f="24591">map</offsets></sc><offsets xml_i="32222" xml_f="32469" txt_i="24591" txt_f="24838">.3 participants can be assured that their safety will be closely monitored and regularly reviewed by a Data Safety and Monitoring Committee. One important question that will arise from the current series of adjuvant and chemo-prevention trials of </offsets><sc><offsets xml_i="32473" xml_f="32475" txt_i="24838" txt_f="24840">ai</offsets></sc><offsets xml_i="32480" xml_f="32563" txt_i="24840" txt_f="24923">s is whether distinct pharmacodynamic effects are associated with the nonsteroidal </offsets><sc><offsets xml_i="32567" xml_f="32569" txt_i="24923" txt_f="24925">ai</offsets></sc><offsets xml_i="32574" xml_f="32687" txt_i="24925" txt_f="25038">s (anastrozole and letrozole) and the steroidal aromatase inactivator (exemestane) that would favour one type of </offsets><sc><offsets xml_i="32691" xml_f="32693" txt_i="25038" txt_f="25040">ai</offsets></sc><offsets xml_i="32698" xml_f="32738" txt_i="25040" txt_f="25080"> over another in the prevention setting.</offsets></p></sec></body><back><ref-list><title>6. REFERENCES</title><ref id="b1-co14_3p089"><label>1</label><citation citation-type="journal"><collab>National Institutes of Health Consensus Development Panel</collab><article-title>National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000</article-title><source>J Natl Cancer Inst Monogr</source><year>2001</year><issue>30</issue><fpage>5</fpage><lpage>15</lpage></citation></ref><ref id="b2-co14_3p089"><label>2</label><citation citation-type="journal"><person-group><name><surname>Ravdin</surname><given-names>PM</given-names></name><name><surname>Cronin</surname><given-names>KA</given-names></name><name><surname>Howlader</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>The decrease in breast-cancer incidence in 2003 in the United States</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>1670</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">17442911</pub-id></citation></ref><ref id="b3-co14_3p089"><label>3</label><citation citation-type="journal"><person-group><name><surname>Colditz</surname><given-names>GA</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><etal></etal></person-group><article-title>Family history, age, and risk of breast cancer: prospective data from the nurses’ health study</article-title><source>JAMA</source><year>1993</year><volume>270</volume><fpage>338</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">8123079</pub-id></citation></ref><ref id="b4-co14_3p089"><label>4</label><citation citation-type="journal"><person-group><name><surname>Lynch</surname><given-names>HT</given-names></name><name><surname>Lynch</surname><given-names>JF</given-names></name></person-group><article-title>Breast cancer genetics in an oncology clinic: 328 consecutive patients</article-title><source>Cancer Genet Cytogenet</source><year>1986</year><volume>22</volume><fpage>369</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">3731052</pub-id></citation></ref><ref id="b5-co14_3p089"><label>5</label><citation citation-type="journal"><person-group><name><surname>Struewing</surname><given-names>JP</given-names></name><name><surname>Hartge</surname><given-names>P</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>The risk of cancer associated with specific mutations of <italic>BRCA1</italic> and <italic>BRCA2</italic> among Ashkenazi Jews</article-title><source>N Engl J Med</source><year>1997</year><volume>336</volume><fpage>1401</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9145676</pub-id></citation></ref><ref id="b6-co14_3p089"><label>6</label><citation citation-type="journal"><person-group><name><surname>Kheifets</surname><given-names>LI</given-names></name><name><surname>Matkin</surname><given-names>C</given-names></name></person-group><article-title>Industrialization, electromagnetic fields, and breast cancer risk</article-title><source>Environ Health Perspect</source><year>1999</year><volume>107 </volume><issue>suppl 1</issue><fpage>145</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">10229714</pub-id></citation></ref><ref id="b7-co14_3p089"><label>7</label><citation citation-type="other">Huff J, Boyd J, Barrett JC. Cellular and molecular mechanisms of hormonal carcinogenesis: environmental influences. Progress in Clinical and Biological Research series. Vol. 394.) New York: Wiley Liss; 1996: 1–479.</citation></ref><ref id="b8-co14_3p089"><label>8</label><citation citation-type="journal"><person-group><name><surname>Mettlin</surname><given-names>C</given-names></name></person-group><article-title>Global breast cancer mortality statistics</article-title><source>CA Cancer J Clin</source><year>1999</year><volume>49</volume><fpage>138</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">10445013</pub-id></citation></ref><ref id="b9-co14_3p089"><label>9</label><citation citation-type="journal"><person-group><name><surname>Vatten</surname><given-names>LJ</given-names></name><name><surname>Kvinnsland</surname><given-names>S</given-names></name></person-group><article-title>Pregnancy-related factors and risk of breast cancer in a prospective study of 29981 Norwegian women</article-title><source>Eur J Cancer</source><year>1992</year><volume>28A</volume><fpage>1148</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">1627386</pub-id></citation></ref><ref id="b10-co14_3p089"><label>10</label><citation citation-type="journal"><person-group><name><surname>Kvinnsland</surname><given-names>S</given-names></name><name><surname>Anker</surname><given-names>G</given-names></name><name><surname>Dirix</surname><given-names>LY</given-names></name><etal></etal></person-group><article-title>High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment</article-title><source>Eur J Cancer</source><year>2000</year><volume>36</volume><fpage>976</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">10885600</pub-id></citation></ref><ref id="b11-co14_3p089"><label>11</label><citation citation-type="journal"><person-group><name><surname>Kaaks</surname><given-names>R</given-names></name><name><surname>Berrino</surname><given-names>F</given-names></name><name><surname>Key</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Serum sex steroids in pre-menopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (epic)</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>755</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">15900045</pub-id></citation></ref><ref id="b12-co14_3p089"><label>12</label><citation citation-type="journal"><person-group><name><surname>Berrino</surname><given-names>F</given-names></name><name><surname>Muti</surname><given-names>P</given-names></name><name><surname>Micheli</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Serum sex hormone levels after menopause and subsequent breast cancer</article-title><source>J Natl Cancer Inst</source><year>1996</year><volume>88</volume><fpage>291</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8614008</pub-id></citation></ref><ref id="b13-co14_3p089"><label>13</label><citation citation-type="journal"><person-group><name><surname>Eliassen</surname><given-names>AH</given-names></name><name><surname>Missmer</surname><given-names>SA</given-names></name><name><surname>Tworoger</surname><given-names>SS</given-names></name><etal></etal></person-group><article-title>Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>98</volume><fpage>1406</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">17018787</pub-id></citation></ref><ref id="b14-co14_3p089"><label>14</label><citation citation-type="journal"><person-group><name><surname>Tworoger</surname><given-names>SS</given-names></name><name><surname>Sluss</surname><given-names>P</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name></person-group><article-title>Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>2476</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">16489055</pub-id></citation></ref><ref id="b15-co14_3p089"><label>15</label><citation citation-type="journal"><person-group><name><surname>Krajcik</surname><given-names>RA</given-names></name><name><surname>Borofsky</surname><given-names>ND</given-names></name><name><surname>Massardo</surname><given-names>S</given-names></name><name><surname>Orentreich</surname><given-names>N</given-names></name></person-group><article-title>Insulin-like growth factor I (igf-i), igf-binding proteins, and breast cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2002</year><volume>11</volume><fpage>1566</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">12496045</pub-id></citation></ref><ref id="b16-co14_3p089"><label>16</label><citation citation-type="journal"><person-group><name><surname>Burroughs</surname><given-names>KD</given-names></name><name><surname>Dunn</surname><given-names>SE</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Taylor</surname><given-names>JA</given-names></name></person-group><article-title>Insulin-like growth factor-i: a key regulator of human cancer risk?</article-title><source>J Natl Cancer Inst</source><year>1999</year><volume>91</volume><fpage>579</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">10203270</pub-id></citation></ref><ref id="b17-co14_3p089"><label>17</label><citation citation-type="journal"><person-group><name><surname>Prentice</surname><given-names>RL</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Greenwald</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Nutrition and physical activity and chronic disease prevention: research strategies and recommendations</article-title><source>J Natl Cancer Inst</source><year>2004</year><volume>96</volume><fpage>1276</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">15339966</pub-id></citation></ref><ref id="b18-co14_3p089"><label>18</label><citation citation-type="journal"><person-group><name><surname>Kotsopoulos</surname><given-names>J</given-names></name><name><surname>Olopado</surname><given-names>OI</given-names></name><name><surname>Ghadirian</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Changes in body weight and the risk of breast cancer in <italic>BRCA1</italic> and <italic>BRCA2</italic> mutation carriers</article-title><source>Breast Cancer Res</source><year>2005</year><volume>7</volume><fpage>R833</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16168130</pub-id></citation></ref><ref id="b19-co14_3p089"><label>19</label><citation citation-type="journal"><person-group><name><surname>Terry</surname><given-names>MB</given-names></name><name><surname>Zhang</surname><given-names>FF</given-names></name><name><surname>Kabat</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Lifetime alcohol intake and breast cancer risk</article-title><source>Ann Epidemiol</source><year>2006</year><volume>16</volume><fpage>230</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16230024</pub-id></citation></ref><ref id="b20-co14_3p089"><label>20</label><citation citation-type="journal"><person-group><name><surname>Rossouw</surname><given-names>JE</given-names></name><name><surname>Anderson</surname><given-names>GL</given-names></name><name><surname>Prentice</surname><given-names>RL</given-names></name><etal></etal></person-group><article-title>Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>321</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">12117397</pub-id></citation></ref><ref id="b21-co14_3p089"><label>21</label><citation citation-type="journal"><person-group><name><surname>Boyd</surname><given-names>N</given-names></name><name><surname>Byng</surname><given-names>J</given-names></name><name><surname>Jong</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study</article-title><source>J Natl Cancer Inst</source><year>1995</year><volume>87</volume><fpage>670</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7752271</pub-id></citation></ref><ref id="b22-co14_3p089"><label>22</label><citation citation-type="journal"><person-group><name><surname>Clarke</surname><given-names>CA</given-names></name><name><surname>Glaser</surname><given-names>SL</given-names></name><name><surname>Uratsu</surname><given-names>CS</given-names></name><name><surname>Selby</surname><given-names>JV</given-names></name><name><surname>Kushi</surname><given-names>LH</given-names></name><name><surname>Herrinton</surname><given-names>LJ</given-names></name></person-group><article-title>Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>e49</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17114650</pub-id></citation></ref><ref id="b23-co14_3p089"><label>23</label><citation citation-type="journal"><person-group><name><surname>Clemons</surname><given-names>M</given-names></name><name><surname>Goss</surname><given-names>P</given-names></name></person-group><article-title>Estrogen and the risk of breast cancer</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>276</fpage><lpage>85</lpage><comment>[Erratum in: N Engl J Med 2001;344:1804]</comment><pub-id pub-id-type="pmid">11172156</pub-id></citation></ref><ref id="b24-co14_3p089"><label>24</label><citation citation-type="journal"><person-group><name><surname>Key</surname><given-names>T</given-names></name><name><surname>Appleby</surname><given-names>P</given-names></name><name><surname>Barnes</surname><given-names>I</given-names></name><name><surname>Reeves</surname><given-names>G</given-names></name></person-group><collab>for the Endogenous Hormones and Breast Cancer Collaborative Group</collab><article-title>Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>94</volume><fpage>606</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">11959894</pub-id></citation></ref><ref id="b25-co14_3p089"><label>25</label><citation citation-type="journal"><person-group><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Costantino</surname><given-names>JP</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><etal></etal></person-group><article-title>Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</article-title><source>J Natl Cancer Inst</source><year>1998</year><volume>90</volume><fpage>1371</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">9747868</pub-id></citation></ref><ref id="b26-co14_3p089"><label>26</label><citation citation-type="journal"><person-group><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Forbes</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>First results from the International Breast Cancer Intervention Study (ibis-i): a randomised prevention trial</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>817</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">12243915</pub-id></citation></ref><ref id="b27-co14_3p089"><label>27</label><citation citation-type="journal"><person-group><name><surname>Vogel</surname><given-names>VG</given-names></name><name><surname>Costantino</surname><given-names>JP</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><etal></etal></person-group><article-title>Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes—the nsabp study of tamoxifen and raloxifene (star) P-2 trial</article-title><source>JAMA</source><year>2006</year><volume>295</volume><fpage>2727</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16754727</pub-id></citation></ref><ref id="b28-co14_3p089"><label>28</label><citation citation-type="journal"><person-group><name><surname>Day</surname><given-names>R</given-names></name><name><surname>Ganz</surname><given-names>PA</given-names></name><name><surname>Costantino</surname><given-names>JP</given-names></name><name><surname>Cronin</surname><given-names>WM</given-names></name><name><surname>Wickerham</surname><given-names>DL</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name></person-group><article-title>Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>2659</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">10561339</pub-id></citation></ref><ref id="b29-co14_3p089"><label>29</label><citation citation-type="journal"><person-group><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Forbes</surname><given-names>JF</given-names></name><name><surname>Sestak</surname><given-names>I</given-names></name><etal></etal></person-group><collab>for the International Breast Cancer Intervention Study i Investigators</collab><article-title>Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized ibis-i trial</article-title><source>J Natl Cancer Inst</source><year>2007</year><volume>99</volume><fpage>272</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">17312304</pub-id></citation></ref><ref id="b30-co14_3p089"><label>30</label><citation citation-type="journal"><person-group><name><surname>Buzdar</surname><given-names>A</given-names></name><name><surname>Jonat</surname><given-names>W</given-names></name><name><surname>Howell</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in post-menopausal women with advanced breast cancer: results of overview analysis of two phase iii trials. Arimidex Study Group</article-title><source>J Clin Oncol</source><year>1996</year><volume>14</volume><fpage>2000</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">8683230</pub-id></citation></ref><ref id="b31-co14_3p089"><label>31</label><citation citation-type="journal"><person-group><name><surname>Dombernowsky</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Falkson</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>453</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">9469328</pub-id></citation></ref><ref id="b32-co14_3p089"><label>32</label><citation citation-type="journal"><person-group><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Wiseman</surname><given-names>LR</given-names></name></person-group><article-title>Exemestane</article-title><source>Drugs</source><year>1999</year><volume>58</volume><fpage>675</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10551437</pub-id></citation></ref><ref id="b33-co14_3p089"><label>33</label><citation citation-type="journal"><person-group><name><surname>Kaufmann</surname><given-names>M</given-names></name><name><surname>Bajetta</surname><given-names>E</given-names></name><name><surname>Dirix</surname><given-names>LY</given-names></name><etal></etal></person-group><article-title>Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase iii randomized double-blind trial. The Exemestane Study Group</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>1399</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">10735887</pub-id></citation></ref><ref id="b34-co14_3p089"><label>34</label><citation citation-type="journal"><person-group><name><surname>Baum</surname><given-names>M</given-names></name><name><surname>Budzar</surname><given-names>AU</given-names></name><name><surname>Cuzick</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the atac randomised trial</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>2131</fpage><lpage>9</lpage><comment>[Erratum in: Lancet 2002;360:1520]</comment><pub-id pub-id-type="pmid">12090977</pub-id></citation></ref><ref id="b35-co14_3p089"><label>35</label><citation citation-type="journal"><person-group><name><surname>Coombes</surname><given-names>RC</given-names></name><name><surname>Paridaens</surname><given-names>R</given-names></name><name><surname>Jassem</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>First mature analysis of the Intergroup Exemestane Study (abstract LBA527)</article-title><source>J Clin Oncol</source><year>2006</year><fpage>24</fpage></citation></ref><ref id="b36-co14_3p089"><label>36</label><citation citation-type="journal"><person-group><name><surname>Coombes</surname><given-names>RC</given-names></name><name><surname>Kilburn</surname><given-names>LS</given-names></name><name><surname>Snowdon</surname><given-names>CF</given-names></name><etal></etal></person-group><article-title>Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial</article-title><source>Lancet</source><year>2007</year><volume>369</volume><fpage>559</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">17307102</pub-id></citation></ref><ref id="b37-co14_3p089"><label>37</label><citation citation-type="journal"><person-group><name><surname>Goss</surname><given-names>PE</given-names></name><name><surname>Ingle</surname><given-names>JN</given-names></name><name><surname>Martino</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>1793</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">14551341</pub-id></citation></ref><ref id="b38-co14_3p089"><label>38</label><citation citation-type="journal"><person-group><name><surname>Goss</surname><given-names>PE</given-names></name><name><surname>Ingle</surname><given-names>JN</given-names></name><name><surname>Martino</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from ncic ctg ma.17</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>1262</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">16145047</pub-id></citation></ref><ref id="b39-co14_3p089"><label>39</label><citation citation-type="journal"><person-group><name><surname>Thurlimann</surname><given-names>B</given-names></name><name><surname>Keshaviah</surname><given-names>A</given-names></name><name><surname>Coates</surname><given-names>AS</given-names></name><etal></etal></person-group><article-title>A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>2747</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16382061</pub-id></citation></ref><ref id="b40-co14_3p089"><label>40</label><citation citation-type="journal"><person-group><name><surname>Winer</surname><given-names>EP</given-names></name><name><surname>Hudis</surname><given-names>C</given-names></name><name><surname>Burstein</surname><given-names>HJ</given-names></name><etal></etal></person-group><article-title>American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>619</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">15545664</pub-id></citation></ref><ref id="b41-co14_3p089"><label>41</label><citation citation-type="journal"><person-group><name><surname>Gunson</surname><given-names>DE</given-names></name><name><surname>Steele</surname><given-names>RE</given-names></name><name><surname>Chau</surname><given-names>RY</given-names></name></person-group><article-title>Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor</article-title><source>Br J Cancer</source><year>1995</year><volume>72</volume><fpage>72</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">7639848</pub-id></citation></ref><ref id="b42-co14_3p089"><label>42</label><citation citation-type="journal"><person-group><name><surname>Lubet</surname><given-names>RA</given-names></name><name><surname>Steele</surname><given-names>VE</given-names></name><name><surname>Casebolt</surname><given-names>TL</given-names></name><name><surname>Eto</surname><given-names>I</given-names></name><name><surname>Kelloff</surname><given-names>GJ</given-names></name><name><surname>Grubbs</surname><given-names>CJ</given-names></name></person-group><article-title>Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (mnu)-induced mammary tumor model in Sprague–Dawley rats</article-title><source>Carcinogenesis</source><year>1994</year><volume>15</volume><fpage>2775</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">8001234</pub-id></citation></ref><ref id="b43-co14_3p089"><label>43</label><citation citation-type="journal"><person-group><name><surname>Schieweck</surname><given-names>K</given-names></name><name><surname>Bhatnagar</surname><given-names>AS</given-names></name><name><surname>Batzl</surname><given-names>C</given-names></name><name><surname>Lang</surname><given-names>M</given-names></name></person-group><article-title>Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors</article-title><source>J Steroid Biochem Mol Biol</source><year>1993</year><volume>44</volume><fpage>633</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8476774</pub-id></citation></ref><ref id="b44-co14_3p089"><label>44</label><citation citation-type="journal"><person-group><name><surname>Bhatnagar</surname><given-names>AS</given-names></name><name><surname>Hausler</surname><given-names>A</given-names></name><name><surname>Schieweck</surname><given-names>K</given-names></name><name><surname>Lang</surname><given-names>M</given-names></name><name><surname>Bowman</surname><given-names>R</given-names></name></person-group><article-title>Highly selective inhibition of estrogen biosynthesis by cgs 20267, a new non-steroidal aromatase inhibitor</article-title><source>J Steroid Biochem Mol Biol</source><year>1990</year><volume>37</volume><fpage>1021</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">2149502</pub-id></citation></ref><ref id="b45-co14_3p089"><label>45</label><citation citation-type="journal"><person-group><name><surname>O’Neill</surname><given-names>GP</given-names></name><name><surname>Ford Hutchinson</surname><given-names>AW</given-names></name></person-group><article-title>Expression of messenger-rna for cyclooxygenase-1 and cyclooxygenase-2 in human tissues</article-title><source>FEBS Lett</source><year>1993</year><volume>330</volume><fpage>156</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">8365485</pub-id></citation></ref><ref id="b46-co14_3p089"><label>46</label><citation citation-type="journal"><person-group><name><surname>Hwang</surname><given-names>D</given-names></name><name><surname>Scollard</surname><given-names>D</given-names></name><name><surname>Byrne</surname><given-names>J</given-names></name><name><surname>Levine</surname><given-names>E</given-names></name></person-group><article-title>Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer</article-title><source>J Natl Cancer Inst</source><year>1998</year><volume>90</volume><fpage>455</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">9521170</pub-id></citation></ref><ref id="b47-co14_3p089"><label>47</label><citation citation-type="journal"><person-group><name><surname>Liu</surname><given-names>XH</given-names></name><name><surname>Rose</surname><given-names>DP</given-names></name></person-group><article-title>Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>5125</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8912844</pub-id></citation></ref><ref id="b48-co14_3p089"><label>48</label><citation citation-type="journal"><person-group><name><surname>Khuder</surname><given-names>SA</given-names></name><name><surname>Mutgi</surname><given-names>AB</given-names></name></person-group><article-title>Breast cancer and nsaid use: a meta-analysis</article-title><source>Br J Cancer</source><year>2001</year><volume>84</volume><fpage>1188</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">11336469</pub-id></citation></ref><ref id="b49-co14_3p089"><label>49</label><citation citation-type="journal"><person-group><name><surname>Pesenti</surname><given-names>E</given-names></name><name><surname>Masferrer</surname><given-names>JL</given-names></name><name><surname>di Salle</surname><given-names>E</given-names></name></person-group><article-title>Effect of exemestane and celecoxib alone or in combination on dmba-induced mammary carcinoma in rats (abstract 445)</article-title><source>Breast Cancer Res Treat</source><year>2001</year><volume>69</volume><fpage>288</fpage></citation></ref><ref id="b50-co14_3p089"><label>50</label><citation citation-type="journal"><person-group><name><surname>Bresalier</surname><given-names>RS</given-names></name><name><surname>Sandler</surname><given-names>RS</given-names></name><name><surname>Quan</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Cardiovascular events associated with rofecoxib in a colorectal adenoma chemo-prevention trial</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>1092</fpage><lpage>102</lpage><comment>[Erratum in: N Engl J Med 2006;355:221]</comment><pub-id pub-id-type="pmid">15713943</pub-id></citation></ref><ref id="b51-co14_3p089"><label>51</label><citation citation-type="journal"><person-group><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><etal></etal></person-group><article-title>Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>1071</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">15713944</pub-id></citation></ref><ref id="b52-co14_3p089"><label>52</label><citation citation-type="journal"><person-group><name><surname>Port</surname><given-names>ER</given-names></name><name><surname>Montgomery</surname><given-names>LL</given-names></name><name><surname>Heerdt</surname><given-names>AS</given-names></name><name><surname>Borgen</surname><given-names>PI</given-names></name></person-group><article-title>Patient reluctance toward tamoxifen use for breast cancer primary prevention</article-title><source>Ann Surg Oncol</source><year>2001</year><volume>8</volume><fpage>580</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11508619</pub-id></citation></ref><ref id="b53-co14_3p089"><label>53</label><citation citation-type="journal"><person-group><name><surname>Lewis</surname><given-names>CL</given-names></name><name><surname>Kinsinger</surname><given-names>LS</given-names></name><name><surname>Harris</surname><given-names>RP</given-names></name><name><surname>Schwartz</surname><given-names>RJ</given-names></name></person-group><article-title>Breast cancer risk in primary care: implications for chemoprevention</article-title><source>Arch Intern Med</source><year>2004</year><volume>164</volume><fpage>1897</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">15451765</pub-id></citation></ref><ref id="b54-co14_3p089"><label>54</label><citation citation-type="journal"><person-group><name><surname>Taylor</surname><given-names>R</given-names></name><name><surname>Taguchi</surname><given-names>K</given-names></name></person-group><article-title>Tamoxifen for breast cancer chemo-prevention: low uptake by high-risk women after evaluation of a breast lump</article-title><source>Ann Fam Med</source><year>2005</year><volume>3</volume><fpage>242</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15928228</pub-id></citation></ref><ref id="b55-co14_3p089"><label>55</label><citation citation-type="journal"><person-group><name><surname>Salant</surname><given-names>T</given-names></name><name><surname>Ganschow</surname><given-names>PS</given-names></name><name><surname>Olopade</surname><given-names>OI</given-names></name><name><surname>Lauderdale</surname><given-names>DS</given-names></name></person-group><article-title>“Why take it if you don’t have anything?” Breast cancer risk perceptions and prevention choices at a public hospital”</article-title><source>J Gen Intern Med</source><year>2006</year><volume>21</volume><fpage>779</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">16808782</pub-id></citation></ref><ref id="b56-co14_3p089"><label>56</label><citation citation-type="journal"><person-group><name><surname>Chlebowski</surname><given-names>RT</given-names></name><name><surname>Col</surname><given-names>N</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><etal></etal></person-group><article-title>American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>3328</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12149307</pub-id></citation></ref><ref id="b57-co14_3p089"><label>57</label><citation citation-type="journal"><person-group><name><surname>Haas</surname><given-names>JS</given-names></name><name><surname>Kaplan</surname><given-names>CP</given-names></name><name><surname>Gregorich</surname><given-names>SE</given-names></name><name><surname>Perez–Stable</surname><given-names>EJ</given-names></name><name><surname>Des</surname><given-names>JG</given-names></name></person-group><article-title>Do physicians tailor their recommendations for breast cancer risk reduction based on patient’s risk?</article-title><source>J Gen Intern Med</source><year>2004</year><volume>19</volume><fpage>302</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15061738</pub-id></citation></ref><ref id="b58-co14_3p089"><label>58</label><citation citation-type="journal"><person-group><name><surname>Kaplan</surname><given-names>CP</given-names></name><name><surname>Haas</surname><given-names>JS</given-names></name><name><surname>Perez–Stable</surname><given-names>EJ</given-names></name><name><surname>Des</surname><given-names>JG</given-names></name><name><surname>Gregorich</surname><given-names>SE</given-names></name></person-group><article-title>Factors affecting breast cancer risk reduction practices among California physicians</article-title><source>Prev Med</source><year>2005</year><volume>41</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">15916987</pub-id></citation></ref><ref id="b59-co14_3p089"><label>59</label><citation citation-type="journal"><person-group><name><surname>Armstrong</surname><given-names>K</given-names></name><name><surname>Quistberg</surname><given-names>DA</given-names></name><name><surname>Micco</surname><given-names>E</given-names></name><name><surname>Domchek</surname><given-names>S</given-names></name><name><surname>Guerra</surname><given-names>C</given-names></name></person-group><article-title>Prescription of tamoxifen for breast cancer prevention by primary care physicians</article-title><source>Arch Intern Med</source><year>2006</year><volume>166</volume><fpage>2260</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17101945</pub-id></citation></ref><ref id="b60-co14_3p089"><label>60</label><citation citation-type="journal"><person-group><name><surname>Freedman</surname><given-names>AN</given-names></name><name><surname>Seminara</surname><given-names>D</given-names></name><name><surname>Gail</surname><given-names>MH</given-names></name><etal></etal></person-group><article-title>Cancer risk prediction models: a workshop on development, evaluation, and application</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>715</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15900041</pub-id></citation></ref><ref id="b61-co14_3p089"><label>61</label><citation citation-type="journal"><person-group><name><surname>Gail</surname><given-names>MH</given-names></name><name><surname>Brinton</surname><given-names>LA</given-names></name><name><surname>Byar</surname><given-names>DP</given-names></name><etal></etal></person-group><article-title>Projecting individualized probabilities of developing breast cancer for white females who are being examined annually</article-title><source>J Natl Cancer Inst</source><year>1989</year><volume>81</volume><fpage>1879</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">2593165</pub-id></citation></ref><ref id="b62-co14_3p089"><label>62</label><citation citation-type="other">United States, National Institutes of Health, National Cancer Institute (<sc>nci</sc>). Breast cancer risk assessment tool (Web resource). Bethesda: <sc>nci</sc>; n.d. [Available at: <ext-link ext-link-type="uri" xlink:href="www.cancer.gov/bcrisktool/">www.cancer.gov/bcrisktool/</ext-link>; cited May 8, 2007]</citation></ref><ref id="b63-co14_3p089"><label>63</label><citation citation-type="other">Canadian Cancer Society and the National Cancer Institute of Canada. <italic>Canadian Cancer Statistics 2006.</italic> Toronto: Canadian Cancer Society; 2006.</citation></ref><ref id="b64-co14_3p089"><label>64</label><citation citation-type="journal"><person-group><name><surname>Elmore</surname><given-names>JG</given-names></name><name><surname>Fletcher</surname><given-names>SW</given-names></name></person-group><article-title>The risk of cancer risk prediction: “what is my risk of getting breast cancer?</article-title><source>J Natl Cancer Inst</source><year>2006</year><volume>98</volume><fpage>1673</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17148763</pub-id></citation></ref><ref id="b65-co14_3p089"><label>65</label><citation citation-type="journal"><person-group><name><surname>Chlebowski</surname><given-names>RT</given-names></name><name><surname>Anderson</surname><given-names>GL</given-names></name><name><surname>Geller</surname><given-names>M</given-names></name><name><surname>Col</surname><given-names>N</given-names></name></person-group><article-title>Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use</article-title><source>Clin Breast Cancer</source><year>2006</year><volume>6</volume><issue>suppl 2</issue><fpage>S58</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">16595028</pub-id></citation></ref><ref id="b66-co14_3p089"><label>66</label><citation citation-type="journal"><person-group><name><surname>Chien</surname><given-names>AJ</given-names></name><name><surname>Goss</surname><given-names>PE</given-names></name></person-group><article-title>Aromatase inhibitors and bone health in women with breast cancer</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>5305</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17114665</pub-id></citation></ref></ref-list></back></article>